Medicenna Therapeutics Corp. GAAP EPS of -C$0.22
Seeking Alpha ·
Medicenna Therapeutics Corp. press release ( MDNA:CA ): FY GAAP EPS of -C$0.22. Medicenna exited the fiscal year ended March 31, 2026, with cash and cash equivalents of C$6.3 million. For the year ended March 31, 2026, the Company reported total operating costs of C$22.4 million compared to total operating costs of C$20.4 million for the year ended March 31, 2025. Medicenna Therapeutics Corp. (MDNA:CA) Presents at 2026 Bloom Burton & Co. Healthcare Investor Conference - Slideshow Medicenna launches marketed public offering of securities Historical earnings data for Medicenna Therapeutics Corp. Financial information for Medicenna Therapeutics Corp.
DYAX Investor Sentiment
Bullish (Long) 45% · Bearish (Short) 55%
271 participants
Related News
- Citi sees airline earnings beats, upgrades Allegiant on merger synergies
- i-80 Gold surges after terminating offtake agreement with Vox Royalty
- Netflix's 45% plunge: One-year slide sends shares to the largest 200-day MA gap in 4 years
- Medicare GLP-1 Bridge: What to expect
- Apple can't shield buyers from Al's memory crunch anymore
- Big Tech’s Quiet Diversification Out of Taiwan Is the Ultimate Catalyst for Intel’s Turnaround